TY - JOUR T1 - Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland JF - medRxiv DO - 10.1101/2021.03.05.21252520 SP - 2021.03.05.21252520 AU - Chaoran Chen AU - Sarah Nadeau AU - Ivan Topolsky AU - Marc Manceau AU - Jana S. Huisman AU - Kim Philipp Jablonski AU - Lara Fuhrmann AU - David Dreifuss AU - Katharina Jahn AU - Christiane Beckmann AU - Maurice Redondo AU - Olivier Kobel AU - Christoph Noppen AU - Lorenz Risch AU - Martin Risch AU - Nadia Wohlwend AU - Sinem Kas AU - Thomas Bodmer AU - Tim Roloff AU - Madlen Stange AU - Adrian Egli AU - Isabella Eckerle AU - Laurent Kaiser AU - Rebecca Denes AU - Mirjam Feldkamp AU - Ina Nissen AU - Natascha Santacroce AU - Elodie Burcklen AU - Catharine Aquino AU - Andreia Cabral de Gouvea AU - Maria Domenica Moccia AU - Simon GrĂ¼ter AU - Timothy Sykes AU - Lennart Opitz AU - Griffin White AU - Laura Neff AU - Doris Popovic AU - Andrea Patrignani AU - Jay Tracy AU - Ralph Schlapbach AU - Emmanouil T. Dermitzakis AU - Keith Harshman AU - Ioannis Xenarios AU - Henri Pegeot AU - Lorenzo Cerutti AU - Deborah Penet AU - Anthony Blin AU - Melyssa Elies AU - Christian Althaus AU - Christian Beisel AU - Niko Beerenwinkel AU - Martin Ackermann AU - Tanja Stadler Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/16/2021.03.05.21252520.abstract N2 - Background In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now coined B.1.1.7. Based on the UK data and later additional data from other countries, a transmission advantage of around 40-80% was estimated for this variant [1, 2, 3].Aim The goal of this study is to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time for data from Switzerland.Methods We collected genomic surveillance data from 11.8% of all SARS-CoV-2 confirmed cases across Switzerland between 14.12.2020 and 11.03.2021. It allows us to determine the relative proportion of the B.1.1.7 variant on a daily basis and to quantify the transmission advantage of the B.1.1.7 variant on a national and a regional scale.Results We propose a transmission advantage of 43-52% of B.1.1.7 compared to the other circulating variants. Further, we estimate a reproductive number for B.1.1.7 above 1 for Jan. 1, 2021 until now while the reproductive number for the other variants was below 1. In particular, for the time period up to Jan. 17 we obtain a reproductive number of 1.24 [1.07-1.41] and from Jan. 18 until March 1 we obtain 1.18 [1.06-1.30] based on the whole genome sequencing data. For March 10-16, we obtain 1.14 [1.00-1.26] based on all confirmed cases among which B.1.1.7 is dominant at this stage. Switzerland tightened measures on 18.01.2021 and released measures on 01.03.2021.Conclusion In summary, the dynamics of increase in the frequency of B.1.1.7 is as expected based on the observations in the UK. B.1.1.7 increased in absolute numbers exponentially with the point estimate for the doubling time being around 2-3.5 weeks. Our plots are available online and are currently regularly updated with new data to closely monitor the spread of B.1.1.7.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTS acknowledges funding from the Swiss National Science foundation (Special Call on Coronaviruses; 31CA30_196267 and 31CA30_196348). CA received funding from the European Union Horizon 2020 research and innovation programme - project EpiPose (No 101003688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics commission (Ethikkommission Nordwest- und Zentralschweiz) confirmed that our study is exempt from ethical oversight as it only considers viral RNA but no human data. The final letter is attached.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll used data and code are publicly available. https://github.com/cevo-public/Quantification-of-the-spread-of-a-SARS-CoV-2-variant ER -